Pharma marketers have spent years waiting for claims, waiting for prescriptions, waiting for signals that confirm a patient has already begun their treatment journey.
But by the time a claim appears, the moment of influence has often already passed.
Diagnosis and testing reveal intent far earlier than traditional commercial datasets. They show who is evaluating a condition today, who is testing for a biomarker now, and which physicians are on the cusp of making a treatment decision. Yet historically, marketing teams haven’t been able to act on this early intent because diagnostic data wasn’t integrated into the tools they use to activate media.
That changes with the partnership between Diaceutics and DeepIntent.
Why Waiting for Claims Is Too Late
Waiting for claims has trained marketers to engage long after the decisive clinical moments have occurred. Claims-based targeting is inherently retrospective often lagging months behind real-world clinical activity.
With diseases that progress quickly, competitive markets, and increasingly complex biomarker-driven therapies, acting after the point of decision simply isn’t enough.
Pharma needs a way to engage physicians upstream when diagnostic activity first signals treatment intent.
Real-Time Diagnostic Signals, Now Fully Actionable in DeepIntent’s DSP
Through this partnership, Diaceutics’ AI-driven diagnostic, lab, and genomic insights are now embedded directly inside DeepIntent’s industry-leading healthcare DSP.
Marketers can plan, activate, and optimize campaigns using more than 100 prebuilt diagnostic and genomic audience segments covering chronic diseases, rare diseases, and precision oncology.
This is a fundamental shift in how treatment intent is identified and acted upon.
With diagnostically informed audiences available natively within DeepIntent, brands can:
- Target HCPs based on real clinical activity happening today vs months-old claims.
- Close the recency gap by activating campaigns the moment diagnostic or lab triggers occur.
- Identify hidden treaters not visible in claims data but evident in diagnostic patterns.
- Engage physicians earlier—when influence is still possible and decisions are still being shaped.
This is the earliest, most actionable view of treatment intent the industry has ever had access to.
Meeting Physicians at the Moment of Decision
“When influence matters most” has always been a guiding principle in HCP marketing. But operationally, marketing teams have been constrained by the timing of traditional datasets.
Now, DeepIntent’s DSP trusted for its healthcare-specific optimization, identity capabilities, and proven script lift becomes the activation engine for real-time clinical intelligence.
This means marketers can reach physicians:
- When a new diagnostic test is ordered
- When a biomarker result signals eligibility
- When a rare disease evaluation begins
- When a treatment decision is imminent
Not after a script is written.
Not after a claim hits.
But in the moment.
DeepIntent already helps marketers achieve measurable outcomes through real-world clinical signals and privacy-safe optimization at scale. By integrating Diaceutics’ clinical and genomic intelligence, the platform becomes even more powerful.
For marketers, that means:
- Earlier visibility into treatment intent
- New pathways to influence before decisions are locked in
- More accurate audience qualification for complex precision therapies
- Campaign performance tied to real-world clinical triggers
This is precision medicine marketing operating at the speed of clinical reality.
A New Standard for HCP Engagement: Act on Intent Before It Becomes a Claim
For the first time, diagnostic and genomic signals aren’t just insights they’re actionable media audiences inside one of the pharma industry’s most advanced DSPs.
Brands can now influence the journey at the right time, for the right patient, through the right physician.
Real-time diagnostic intent is the new competitive advantage.
And with Diaceutics + DeepIntent, pharma marketers finally have the ability to see it and act on it when it matters most.
Talk to one of our data experts today to learn more
